Kendall v. Pharmaceutical Product Development, LLC

CourtDistrict Court, E.D. North Carolina
DecidedMarch 31, 2021
Docket7:20-cv-00071
StatusUnknown

This text of Kendall v. Pharmaceutical Product Development, LLC (Kendall v. Pharmaceutical Product Development, LLC) is published on Counsel Stack Legal Research, covering District Court, E.D. North Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kendall v. Pharmaceutical Product Development, LLC, (E.D.N.C. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF NORTH CAROLINA SOUTHERN DIVISION No. 7:20-CV-71-D

KARL KENDALL, SUZANNE RAINEY, _) and VINCENZO PERNICE, ) Plaintiffs, V. ORDER PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC, et al., Defendants.

On April 15, 2020, Karl Kendall, Suzanne Rainey, and Vincenzo Pernice (collectively, “plaintiffs”) filed a complaint against Pharmaceutical Product Development, LLC (“PPD”), the Board of Directors of PPD (the “Board”), the Benefits Administrative Committee (the “Committee”), and John Does 1-30 (collectively, “defendants”) [D.E. 1]. Plaintiffs allege that the Committee breached its fiduciary duties of loyalty and prudence under section 404(a) of the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1104(a) (count one), and that PPD and the Board breached their duty to monitor the Committee (count two). See id. On July 31, 2020, pursuant to Federal Rules of Civil Procedure 12(b)(1) and (b)(6), defendants moved to dismiss the complaint [D.E. 19], and filed a memorandum in support [D.E. 20]. On August 21, 2020, plaintiffs responded in opposition [D.E. 21]. On September 4, 2020, defendants replied [D.E. 22]. As explained below, the court grants in part and denies in part defendants’ motion to dismiss, dismisses a portion of the claims, and dismisses plaintiffs’ request for injunctive relief.

I. This putative class action concerns defendants’ selection and maintenance of investment options in the PPD Retirement Savings Plan (the “Plan”). See Compl. [D.E. 1]. PPD is a leading global contract research organization and pharmaceutical product development company based in Wilmington, North Carolina. See id. [| 18-19. PPD sponsors the Plan—a defined contribution, individual account plan under ERISA § 3(34), 29 U.S.C. § 1002(34)—for eligible employees. See id. 18, 33-35. Employees make pre- and post- tax contributions to individual accounts, and PPD makes matching contributions. See id. J] 33-41. Between 2014 and 2020 (the “Class Period”), the Plan offered participants various investment options. See id. § 43. PPD is the named fiduciary responsible for administering the Plan. See id. [{] 20-24. PPD, acting through the Board, delegated fiduciary responsibilities for selection and retention of the Plan’s investment options to the Committee. See id. f] 25-31. The Plan’s recordkeeper is Massachusetts Mutual Life Insurance Company (“Mass Mutual”). See id. | 113. Recordkeeping consists of administrative tasks including claims processing, loan processing, disclosures, participant education, and other consulting services. See id. Plaintiffs are former employees of PPD who allege they participated in the Plan during the Class Period. See id. J 13-15. Plaintiffs admit that they lack knowledge of defendants’

_ decisionmaking process with respect to the Plan. See id. { 17. Nonetheless, plaintiffs allege that defendants “failed to have a proper system of review in place to ensure that participants in the Plan were being charged appropriate and reasonable fees for the Plan’s investment options.” Id. { 63. Plaintiffs also allege that defendants failed to leverage the size of the Plan to negotiate for lower expense ratios for certain investment options maintained or added to the Plan during the Class Period and lower recordkeeping and administrative fees. See id. Pursuant to ERISA sections 409 and 502,

29 U.S.C. §§ 1109 and 1132, plaintiffs bring a class action on behalf of all participants and beneficiaries of the Plan during the Class Period against defendants in their fiduciary capacities. See id. 1, 47-53. Plaintiffs allege that the Committee breached its fiduciary duties in failing to investigate and select lower cost alternative funds including (1) lower fee share classes, (2) separate accounts or collective trusts as alternatives to mutual funds, and (3) passively-managed funds over actively- managed funds. See id. 76-112. Plaintiffs also allege that the Committee breached its fiduciary duties in failing to monitor recordkeeping fees. See id. FJ 113-31, 135. Count one alleges that the Committee breached its fiduciary duties of loyalty and prudence under ERISA § 404(a), 29 U.S.C. § 1104(a). See id. ff 132-38. Count two alleges that PPD and the Board breached their derivative duty to monitor the Committee. See id. ff 139-45. Plaintiffs seek, among other things, monetary and injunctive relief. A motion to dismiss under Rule 12(b)(6) tests the complaint’s legal and factual sufficiency. See Ashcroft v. Iqbal, 556 U.S. 662, 677-80 (2009); Bell Atl. Corp. v. Twombly, 550 U.S. 544, 554-63 (2007); Coleman v. Md. Court of Appeals, 626 F.3d 187, 190 (4th Cir. 2010), aff'd, 566 U.S. 30 (2012); Giarratano v. Johnson, 521 F.3d 298, 302 (4th Cir. 2008). To withstand a Rule 12(b)(6) motion, a pleading “must contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face.” Iqbal, 556 U.S. at 678 (quotation omitted); see Twombly, 550 US. at 570; Giarratano, 521 F.3d at 302. In considering the motion, the court must construe the facts and reasonable inferences “in the light most favorable to [the nonmoving party].” Massey v. Ojaniit, 759 F.3d 343, 352 (4th Cir. 2014) (quotation omitted); see Clatterbuck v. City of Charlottesville, 708 F.3d 549, 557 (4th Cir. 2013), abrogated on other grounds by Reed v. Town of Gilbert, 576 U.S. 155 (2015). A court need not accept as true a complaint’s legal conclusions,

“unwarranted inferences, unreasonable conclusions, or arguments.” Giarratano, 521 F.3d at 302 (quotation omitted); see Iqbal, 556 U.S. at 678-79. Rather, a plaintiff's factual allegations must “nudge[] [his] claims,” Twombly, 550 U.S. at 570, beyond the realm of “mere possibility” into “plausibility.” Iqbal, 556 U.S. at 678-79. When evaluating a motion to dismiss, a court considers the pleadings and any materials “attached or incorporated into the complaint.” E.I. du Pont de Nemours & Co. v. Kolon Indus., Inc., 637 F.3d 435, 448 (4th Cir. 2011); see Fed. R. Civ. P. 10(c); Goines v. Valley Cmty. Servs. Bd., 822 F.3d 159, 165-66 (4th Cir. 2016); Thompson v. Greene, 427 F.3d 263, 268 (4th Cir. 2005). A court also may consider a document submitted by a moving party if it is “integral to the complaint and there is no dispute about the document’s authenticity” without converting the motion into one for summary judgment. Goines, 822 F.3d at 166. “[I]n the event of conflict between the bare allegations of the complaint and any exhibit attached . . . , the exhibit prevails.” Id. (quotation omitted); see Fayetteville Invs. v. Com. Builders, Inc., 936 F.2d 1462, 1465 (4th Cir. 1991). Additionally, a court may take judicial notice of public records. See, e.g., Fed. R. Evid.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

O'Shea v. Littleton
414 U.S. 488 (Supreme Court, 1974)
Warth v. Seldin
422 U.S. 490 (Supreme Court, 1975)
City of Los Angeles v. Lyons
461 U.S. 95 (Supreme Court, 1983)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
LOCKHEED CORP. Et Al. v. SPINK
517 U.S. 882 (Supreme Court, 1996)
Tellabs, Inc. v. Makor Issues & Rights, Ltd.
551 U.S. 308 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Summers v. Earth Island Institute
555 U.S. 488 (Supreme Court, 2009)
Coleman v. Maryland Court of Appeals
626 F.3d 187 (Fourth Circuit, 2010)
Renfro v. Unisys Corp.
671 F.3d 314 (Third Circuit, 2011)
Loomis v. Exelon Corp.
658 F.3d 667 (Seventh Circuit, 2011)
Holloway v. Pagan River Dockside Seafood, Inc.
669 F.3d 448 (Fourth Circuit, 2012)
Charles McNair v. Synapse Grp Inc
672 F.3d 213 (Third Circuit, 2012)
Coleman v. Court of Appeals of Maryland
132 S. Ct. 1327 (Supreme Court, 2012)
David Wayne Evans v. B.F. Perkins Company
166 F.3d 642 (Fourth Circuit, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
Kendall v. Pharmaceutical Product Development, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kendall-v-pharmaceutical-product-development-llc-nced-2021.